Calls for proposals: US CDC, UK-China, Wellcome Trust

Dear All: As we head into the Easter and Passover weekend, three new calls for proposals have emerged! Perhaps one of these is for you?

  • The US CDC has released a Broad Agency Announcement (FY2018-OADS-BAA) seeking proposals for projects across a range of areas (diagnostics, transmission, microbiome disruption, resistance genes in the environment, and stewardship). Initial proposals are due 16 April 2018.
  • Via Innovate UK, the UK Department of Health and Social Care (DHSC) and The Chinese Ministry of Science and Technology (MOST) have announced a competition in which collaborations between UK- and China-based partners can access £10 million (UK) and 60 million Renminbi (China). The topics of interest include Chinese medicines, new agents, improved used of existing agents, and diagnostics. The competition window is 3 April 2018 to 6 June 2018.
  • The Wellcome Trust is opening a Request for Proposals for an evaluation of the likelihood of successful development and implementation for vaccines against pathogens with high levels of antimicrobial resistance, including a survey of the product development landscape and market analysis. The evaluation will identify barriers to the development and implementation for these vaccines and provide recommendations on the development of these vaccines. See this link for more details. Proposals are due 16 April 2018.

For the first two, see below my signature for a bit more detail. All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

CDC’s list of areas: 6 categories spanning 35 AMR-focused topics. Go to this link for the full announcement.

  • New diagnostic, sequencing, and metagenomic tools for AR detection and improved antibiotic use
  • International transmission, colonization, and prevention of AR pathogens
  • Domestic transmission, colonization, and prevention of AR pathogens and C. difficile infections
  • Develop human microbiome disruption indices relevant to AR
  • Resistant pathogens and genes in water systems and the environment and their contribution to human infections
  • Improving antibiotic stewardship

Innovate UK – DHSC – MOST areas of interest: Go to this link for the full announcement

  • explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious bacterial diseases in humans or animals
  • advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
  • identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
  • use modelling and prospective and retrospective clinical studies to maximise the clinical utility of current antibiotics. Focus especially on those against drug-resistant Gram-negative bacteria. Projects must aim to improve the prognosis of patients with extensively drug-resistant infections
  • improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top